WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has completed enrollment in the first pivotal Phase 3 trial of YCANTH for common warts and passed an interim statistical review …
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.